Leveraging regulatory flexibility for methadone take-home dosing to improve retention in treatment for opioid use disorder: A stepped-wedge randomized trial to facilitate clinic level changes
利用美沙酮带回家剂量的监管灵活性来提高阿片类药物使用障碍治疗的保留率:一项促进临床水平变化的阶梯式楔形随机试验
基本信息
- 批准号:10590040
- 负责人:
- 金额:$ 59.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-30 至 2023-09-29
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse eventAffectAfrican AmericanAttitudeBehaviorBeliefBlack raceBusinessesCOVID-19CaringClientClinicClinicalCommunitiesConfusionConnecticutDataDatabasesDevelopmentDoseEmergency department visitEquilibriumEthnic OriginEventHealthcareHomeHospitalizationIatrogenesisIncentivesIndividualInterventionInterviewLatinxLatinx populationLeadershipLegal LiabilityMedicaidMethadoneMethodsModelingMonitorNew YorkNot Hispanic or LatinoOutcomeOverdosePersonsPharmaceutical PreparationsPhaseQuality of lifeRaceRandomizedRecording of previous eventsRegistriesRegulationRelaxationReportingResearchSafetyServicesStigmatizationSystemTestingUniversitiesVariantVisitaddictionadministrative databaseadverse outcomebaseclinical decision-makingclinical practicecohortdashboarddesignexperienceflexibilityhealth care disparityhealth equityimplementation frameworkimprovedintervention effectintervention programmethadone treatmentmortalityopioid treatment programopioid use disorderpaymentprogramspublic health emergencyrandomized trialstemwaiver
项目摘要
Project Summary
Regulatory changes made during the COVID-19 public health emergency (PHE) that relaxed criteria for take-
home dosing (THD) of methadone offer an opportunity to improve retention in care with a lifesaving treatment.
Methadone is a highly effective medication for treating opioid use disorders (OUD) that is provided in opioid
treatment programs (OTPs). Yet, longstanding regulatory restrictions limit the availability of methadone as well
as create demands that heavily burden clients by requiring frequent visits to clinics. The rationale for these
regulations is to safeguard against diversion and overdoses from methadone. Yet, the history and application
of methadone regulations stem from stigmatized and racist notions of people with OUD. Most OTPs are
located within communities with predominantly Black/African American or Latinx populations. Consequently,
Black/African American and Latinx individuals have greater access to methadone than other, less restricted,
medications for OUD. Within OTPs, Black/African American and Latinx individuals are less likely to receive
adequate dosing levels of methadone and have lower retention than non-Hispanic White clients. More flexible
THD may help address disparities in care. Currently, there is a national debate about balancing safety
concerns over more flexible THD against the benefits of client retention and quality of life. Low offering of THD
in many OTPs suggests a need for new data-driven interventions to encourage changes in engrained clinical
workflows and long-standing stigmatizing beliefs about OUD clients. OTP leadership and staff express concern
about misapplying regulatory flexibility, of iatrogenic effects of greater THD, and about legal liability from
overdoses or diversion. Finally, financial concerns mount for organizations that have long based their business
models on billing for frequent in-person medication dispensing. This project stems from a well-established
academic-public partnership in New York State between the Office of Addiction Services and Supports
(OASAS) and research collaborators from New York University, Cornell University, and the University of
Connecticut. We propose a two-phased project to develop then test a multidimensional OTP intervention to
address clinical decision making, regulatory confusion, legal liability concerns, capacity for clinical practice
change, and financial barriers to THD. The intervention will include OTP THD specific dashboards drawn from
multiple State databases. The approach will be informed by the Health Equity Implementation Framework. In
phase 1 (R61), we will employ an explanatory sequential mixed method design to combine analysis of large
state administrative databases—Medicaid, treatment registry, THD reporting—with qualitative interviews to
refine the intervention. In phase 2 (R33), we will conduct a stepped-wedge trial with 36 OTPs (~10,800
Medicaid clients/yr) randomized to 6 cohorts of a six-month long clinic-level intervention over three years. The
trial will test the effects of the intervention on 1) THD; 2) retention in care; and 3) adverse healthcare events.
We will specifically examine the effects of the intervention for Black/African American and Latinx clients.
项目概要
在 COVID-19 公共卫生紧急事件 (PHE) 期间做出的监管变化放宽了采取措施的标准
美沙酮的家庭给药 (THD) 提供了通过挽救生命的治疗来提高护理保留率的机会。
美沙酮是一种治疗阿片类药物使用障碍 (OUD) 的高效药物,以阿片类药物形式提供
治疗计划 (OTP)。然而,长期的监管限制也限制了美沙酮的供应
由于需要频繁去诊所,因此产生了沉重负担的要求。这些的理由
法规的目的是防止美沙酮的转移和过量服用。然而,历史和应用
美沙酮法规的出台源于对 OUD 患者的污名化和种族主义观念。大多数 OTP 是
位于以黑人/非裔美国人或拉丁裔人口为主的社区内。最后,
黑人/非裔美国人和拉丁裔人士比其他受限制较少的人更容易获得美沙酮
OUD 药物。在 OTP 内,黑人/非裔美国人和拉丁裔人士不太可能获得
足够的美沙酮剂量,并且比非西班牙裔白人客户的保留率较低。更灵活
THD 可能有助于解决护理方面的差异。目前,全国范围内正在就平衡安全展开辩论
人们担心更灵活的 THD 会损害客户保留率和生活质量。 THD 低
许多 OTP 表明需要新的数据驱动干预措施来鼓励根深蒂固的临床变化
工作流程和长期以来对 OUD 客户的污名化信念。 OTP领导和员工表达担忧
关于滥用监管灵活性、更大 THD 的医源性影响以及来自
服用过量或转移。最后,对于长期立足其业务的组织来说,财务问题日益严重
频繁亲自配药的计费模型。该项目源于一个完善的
纽约州成瘾服务和支持办公室之间的学术-公共合作伙伴关系
(OASAS)以及来自纽约大学、康奈尔大学和纽约大学的研究合作者
康涅狄格州。我们提出了一个两阶段的项目来开发然后测试多维 OTP 干预措施
解决临床决策、监管混乱、法律责任问题、临床实践能力
变化以及 THD 的财务障碍。干预措施将包括来自 OTP THD 的特定仪表板
多个国家数据库。该方法将遵循健康公平实施框架。在
第 1 阶段 (R61),我们将采用解释性顺序混合方法设计来结合大型分析
州行政数据库——医疗补助、治疗登记、THD 报告——以及定性访谈
细化干预。在第 2 阶段 (R33),我们将使用 36 个 OTP(约 10,800
医疗补助客户/年)随机分为 6 个队列,在三年内进行为期六个月的临床水平干预。这
试验将测试干预措施对 1) THD 的影响; 2) 保留护理; 3) 不良医疗事件。
我们将专门研究干预措施对黑人/非裔美国人和拉丁裔客户的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yuhua Bao其他文献
Yuhua Bao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yuhua Bao', 18)}}的其他基金
Leveraging regulatory flexibility for methadone take-home dosing to improve retention in treatment for opioid use disorder: A stepped-wedge randomized trial to facilitate clinic level changes
利用美沙酮带回家剂量的监管灵活性来提高阿片类药物使用障碍治疗的保留率:一项促进临床水平变化的阶梯式楔形随机试验
- 批准号:
10878304 - 财政年份:2022
- 资助金额:
$ 59.88万 - 项目类别:
Opioid Treatment of Pain in People with Cancer: Intended and unintended consequences of state policies addressing opioid prescribing
阿片类药物治疗癌症患者的疼痛:针对阿片类药物处方的国家政策的有意和无意的后果
- 批准号:
10707114 - 财政年份:2022
- 资助金额:
$ 59.88万 - 项目类别:
Opioid Treatment of Pain in People with Cancer: Intended and unintended consequences of state policies addressing opioid prescribing
阿片类药物治疗癌症患者的疼痛:针对阿片类药物处方的国家政策的有意和无意的后果
- 批准号:
10523193 - 财政年份:2022
- 资助金额:
$ 59.88万 - 项目类别:
Value-based Purchasing in Implementation of Depression Care in Community Clinics
基于价值的采购在社区诊所抑郁症护理实施中的应用
- 批准号:
8748476 - 财政年份:2014
- 资助金额:
$ 59.88万 - 项目类别:
Value-based Purchasing in Implementation of Depression Care in Community Clinics
基于价值的采购在社区诊所抑郁症护理实施中的应用
- 批准号:
8896872 - 财政年份:2014
- 资助金额:
$ 59.88万 - 项目类别:
Value-based Purchasing in Implementation of Depression Care in Community Clinics
基于价值的采购在社区诊所抑郁症护理实施中的应用
- 批准号:
9098799 - 财政年份:2014
- 资助金额:
$ 59.88万 - 项目类别:
Designing Payment and Performance Evaluation for Depression Care Management
设计抑郁症护理管理的付款和绩效评估
- 批准号:
8403410 - 财政年份:2010
- 资助金额:
$ 59.88万 - 项目类别:
Designing Payment and Performance Evaluation for Depression Care Management
设计抑郁症护理管理的付款和绩效评估
- 批准号:
8212235 - 财政年份:2010
- 资助金额:
$ 59.88万 - 项目类别:
Designing Payment and Performance Evaluation for Depression Care Management
设计抑郁症护理管理的付款和绩效评估
- 批准号:
8607209 - 财政年份:2010
- 资助金额:
$ 59.88万 - 项目类别:
Designing Payment and Performance Evaluation for Depression Care Management
设计抑郁症护理管理的付款和绩效评估
- 批准号:
8054237 - 财政年份:2010
- 资助金额:
$ 59.88万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 59.88万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 59.88万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 59.88万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 59.88万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 59.88万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 59.88万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 59.88万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 59.88万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 59.88万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 59.88万 - 项目类别: